| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| General and administrative | 1,118,211 | |||
| Total operating expenses | -1,118,211 | |||
| Loss from operations | -1,118,211 | |||
| Interest income | 24,383 | |||
| Interest expense, related parties | -62,288 | |||
| Change in the fair value of warrant liabilities | -116,894 | |||
| Forgiveness of unrelated vendor payables | 2,142,297 | |||
| Change in fair value of deferred underwriting fee - common stock payable | -756,000 | |||
| Total other income (expense), net | 1,231,498 | |||
| Net income (loss) | 113,287 | |||
| Earnings per share, basic | - | |||
| Earnings per share, diluted | - | |||
| Weighted average number of shares outstanding, basic | 23,301,178 | |||
| Weighted average number of shares outstanding, diluted | 23,301,178 | |||
Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. (LIMN)